Navigating the management of NASH patients with advanced fibrosis in the next decade
16 Apr 2020
About the event
NASH is becoming a leading cause for end-stage liver disease and liver transplant. The presence of advanced fibrosis is a key predictor of liver-related morbidity and mortality and represents a significant unmet clinical need in terms of timely recognition and effective treatment. A faculty of experts in NASH; Professor Arun Sanyal; Professor Jörn Schattenberg; Professor Laurent Castera and; Ms Livia Alimena of the Global Liver Institute; will deliver this educational and interactive symposium. They will discuss the current NASH patient journey; understand how patient and physician challenges align and consider ways in which current tools and therapies may be optimised.
Allergan is a global technology-driven multi-specialty health care company pursuing therapeutic advances to help patients live life to their fullest potential. In making this commitment we work to develop an unparalleled level of insight into patients' wants and needs and into the priorities and concerns of the medical specialists who treat them.